Solesence earnings release, May 12, 2026
Solésence Reports First Quarter 2026 Financial Results
Advances implementation of Transform and Transcend strategic initiative across Operational Excellence and New Technology Commercialization
ROMEOVILLE, Ill., May 12, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced financial results for the first quarter ended March 31, 2026.
“In March, we introduced Transform and Transcend to our investor community, the strategic initiative that we began at the end of 2025,” commented Kevin Cureton, President and Chief Executive Officer. “Our first quarter results reflect our disciplined execution on this initiative, particularly on our first and foundational pillar, operational excellence. Combined with steady early progress in our efforts to further leverage our intellectual property, expand our addressable market, and evolve our service model to capture greater share of the value chain, Solésence is well positioned to drive long-term, sustainable profitability and growth.”
Recent Highlights and Accomplishments
Improved gross margin through disciplined execution of first pillar of Transform & Transcend Initiative: Operational Excellence.
Expanded OTC claims with commercialization of new platform technologies: WHSPR™ and Chromalüm™.
Added financial executive Marc James as new independent Director.
Laura Riffner, Chief Financial Officer, added, “In the first quarter, Solésence’s investments focused on its operational infrastructure, including employee training and organizational restructuring which created near-term pressure on profitability but also resulted in improved efficiency and reduced labor costs across the business. We expect this will position us for improved operational and financial results as we move through the year.”
First Quarter 2026 Financial Highlights
Revenue for the first quarter was $13.0 million, compared to $14.6 million for the same period in 2025.
Gross profit in the first quarter was $3.3 million, compared to $3.4 million for the same period in 2025.
Gross margin in the first quarter was 26%, compared to 23% for the same period in 2025.
Net loss for the first quarter was approximately $0.8 million, compared to net income of approximately $0.08 million for the same period in 2025.
Conference Call
Solésence will host its first quarter conference call on Tuesday, May 12, 2026, at 7:30 a.m. CT, 8:30 a.m. ET, to discuss its financial results and provide a business and financial update. On the call will be Kevin Cureton, President and Chief Executive Officer, and Laura Riffner, Chief Financial Officer.
Webcast Link: https://edge.media-server.com/mmc/p/t9uyyvcs
Dial-In Link: https://register-conf.media-server.com/register/BI8309d9a33aea468ab429e32ef4434b33
To receive the dial-in number, as well as your personalized PIN, you must register at the above link. Once registered, you will also have the option to have the system dial-out to you once the conference call begins. If you forget your PIN prior to the conference call, you can simply re-register.
The call may also be accessed through the Company’s investor relations website, at https://ir.solesence.com/. Please join the conference call at least five minutes before the start time.
FINANCIAL RESULTS AND NON-GAAP INFORMATION
Use of Non-GAAP Financial Information
Solésence believes that the presentation of results excluding certain items, such as non-cash equity compensation charges, provides meaningful supplemental information to both management and investors, facilitating the evaluation of performance across reporting periods. The Company uses these non-GAAP measures for internal planning and reporting purposes. These non-GAAP measures are not in accordance with, or an alternative for, Generally Accepted Accounting Principles (“GAAP”) and may be different from non-GAAP measures used by other companies. The presentation of this additional information is not meant to be considered in isolation or as a substitute for net income or net income per share prepared in accordance with GAAP.
About Solésence, Inc.
Solésence, Inc. (Nasdaq: SLSN) is a leader in scientifically-driven health care solutions across beauty and life science categories. With a mission to deliver joy through innovation, inclusivity and the science of beautiful skin, we have redefined mineral-based sun protection by maximizing transparency, effectiveness, aesthetics, and wearability — empowering individuals to embrace beauty on their own terms. Combining best-in-class skin health solutions with the celebration of self-care, we allow brands to deliver unique product claims and attributes by seamlessly integrating protection, prevention, and treatment technologies into daily use products. Learn more at solesence.com.
Financial statements
Income Statement
SOLESENCE, INC — investors@solesence.com (in thousands except share and per share data)
| SOLESENCE, INC – CONSOLIDATED STATEMENTS OF OPERATIONS – (Unaudited Consolidated Condensed) – Three months ended – March 31, – 2026 | Three months ended – March 31, – 2026 | SOLESENCE, INC – CONSOLIDATED STATEMENTS OF OPERATIONS – (Unaudited Consolidated Condensed) – Three months ended – March 31, – 2025 | Three months ended – March 31, – 2025 | ||
|---|---|---|---|---|---|
| Revenue: | Product revenue | 12,919 | 14,575 | ||
| Revenue: | Other revenue | 38 | 50 | ||
| Revenue: | Net revenue | 12,957 | 14,625 | ||
| Revenue: | Cost of revenue | 9,620 | 11,243 | ||
| Revenue: | Gross profit | 3,337 | 3,382 | ||
| Operating expense: | Research and development expense | 1,042 | 1,018 | ||
| Operating expense: | Selling, general and administrative expense | 2,799 | 2,108 | ||
| Operating expense: | Net (loss) income from operations | -504 | 256 | ||
| Interest income | Interest expense | 263 | 176 | ||
| Interest income | Other nonoperating income | 1 | |||
| Interest income | Net (loss) income before provision for income taxes | -766 | 80 | ||
| Interest income | Net (loss) income | -766 | 80 | ||
| Interest income | Net (loss) income per share-basic | -0.01 | $- | ||
| Interest income | Weighted average number of common shares outstanding - basic | 70,625,494 | 70,103,279 | ||
| Interest income | Net (loss) income per share-diluted | -0.01 | $- | ||
| Interest income | Weighted average number of common shares outstanding - diluted | 70,625,494 | 72,632,116 | ||
| Interest income | SOLESENCE, INC | SOLESENCE, INC | |||
| Interest income | CONSOLIDATED STATEMENTS OF OPERATIONS - EXPANDED SCHEDULE | CONSOLIDATED STATEMENTS OF OPERATIONS - EXPANDED SCHEDULE | |||
| Interest income | (Unaudited Consolidated Condensed) | (Unaudited Consolidated Condensed) | |||
| Interest income | (in thousands except share and per share data) | (in thousands except share and per share data) | |||
| Revenue: | Product revenue | 12,919 | 14,575 | ||
| Revenue: | Other revenue | 38 | 50 | ||
| Revenue: | Net revenue | 12,957 | 14,625 | ||
| Cost of revenue detail: | Depreciation | 302 | 216 | ||
| Cost of revenue detail: | Non-Cash equity compensation | 20 | 27 | ||
| Cost of revenue detail: | Other costs of revenue | 9,298 | 11,000 | ||
| Cost of revenue detail: | Cost of revenue | 9,620 | 11,243 | ||
| Cost of revenue detail: | Gross profit | 3,337 | 3,382 | ||
| Research and development expense detail: | Depreciation | 4 | 4 | ||
| Research and development expense detail: | Non-Cash equity compensation | 18 | 27 | ||
| Research and development expense detail: | Other research and development expense | 1,020 | 987 | ||
| Research and development expense detail: | Research and development expense | 1,042 | 1,018 | ||
| Selling, general and administrative expense detail: | Depreciation and amortization | 6 | 6 | ||
| Selling, general and administrative expense detail: | Non-Cash equity compensation | 46 | 73 | ||
| Selling, general and administrative expense detail: | Other selling, general and administrative expense | 2,747 | 2,029 | ||
| Selling, general and administrative expense detail: | Selling, general and administrative expense | 2,799 | 2,108 | ||
| Selling, general and administrative expense detail: | Net (loss) income from operations | -504 | 256 | ||
| Interest income | Interest expense | 263 | 176 | ||
| Interest income | Other nonoperating income | 1 | |||
| Interest income | Net (loss) income before provision for income taxes | -766 | 80 | ||
| Interest income | Net (loss) income | -766 | 80 | ||
| Non-GAAP Disclosure (see note regarding Non-GAAP disclosures): | Addback Interest, net | 263 | 176 | ||
| Non-GAAP Disclosure (see note regarding Non-GAAP disclosures): | Addback Depreciation/Amortization | 312 | 226 | ||
| Non-GAAP Disclosure (see note regarding Non-GAAP disclosures): | Addback Non-Cash Equity Compensation | 84 | 127 | ||
| Non-GAAP Disclosure (see note regarding Non-GAAP disclosures): | Adjusted EBITDA | -107 | 609 |
Balance Sheet
SOLESENCE, INC — investors@solesence.com (in thousands)
| SOLESENCE, INC – CONSOLIDATED BALANCE SHEETS – (Unaudited Consolidated Condensed) – March 31, – 2026 – (Unaudited) | SOLESENCE, INC – CONSOLIDATED BALANCE SHEETS – (Unaudited Consolidated Condensed) – December 31, – 2025 | ||
|---|---|---|---|
| Current assets: | Cash | 573 | 1,288 |
| Current assets: | Trade accounts receivable | 7,246 | 7,642 |
| Current assets: | Allowance for credit losses | -867 | -806 |
| Current assets: | Trade accounts receivable, net | 6,379 | 6,836 |
| Current assets: | Inventories, net | 17,559 | 18,511 |
| Current assets: | Prepaid expenses and other current assets | 1,902 | 2,141 |
| Current assets: | Total current assets | 26,413 | 28,776 |
| Current assets: | Equipment and leasehold improvements, net | 14,746 | 14,329 |
| Current assets: | Operating leases, right of use | 6,598 | 6,913 |
| Current assets: | Other assets, net | 37 | 37 |
| Current assets: | Total assets | 47,794 | 50,055 |
| Current liabilities: | Line of credit, accounts receivable, related party | 3,047 | 4,767 |
| Current liabilities: | Current portion of operating lease obligations | 1,296 | 1,255 |
| Current liabilities: | Accounts payable | 4,672 | 4,098 |
| Current liabilities: | Deferred revenue | 1,165 | 930 |
| Current liabilities: | Accrued expenses | 2,511 | 2,879 |
| Current liabilities: | Total current liabilities | 12,691 | 13,929 |
| Current liabilities: | Long-term portion of operating lease obligations | 7,440 | 7,798 |
| Current liabilities: | Long-term portion of line of credit, inventory, related party | 9,500 | 9,500 |
| Current liabilities: | Long-term portion of debt, related parties | 1,000 | 1,000 |
| Current liabilities: | Asset retirement obligations | 196 | 194 |
| Current liabilities: | Total long-term liabilities | 18,136 | 18,492 |
Full release
Forward-Looking Statements... (truncated) mix flexibility in light of customer demand; the Company’s limited marketing experience; changes in development and distribution relationships; the impact of competitive products and technologies; the Company’s dependence on patents and protection of proprietary information; the resolution of litigation in which the Company may become involved; the impact of any potential new government regulations that could be difficult to respond to or too costly to comply with while remaining financially viable; the ability of the Company to maintain an appropriate electronic trading venue; and other factors described in the Company’s Form 10-K filed March 31, 2026. In addition, the Company’s forward-looking statements could be affected by general industry and market conditions and growth rates. Except as required by federal securities laws, the Company undertakes no obligation to update or revise these forward-looking statements to reflect new events, uncertainties, or other contingencies.
Media Contact: media@solesence.com
Investor Relations Contact: investors@solesence.com